MIMIVAX
MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure their patients. The company was founded in 2012 and is headquartered in Buffalo, New York.
MIMIVAX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Buffalo, New York, United States
Country:
United States
Website Url:
http://www.mimivax.com
Total Employee:
1+
Status:
Active
Contact:
(716) 845-8850
Total Funding:
1.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Current Employees Featured
Founder
Official Site Inspections
http://www.mimivax.com Semrush global rank: 4.83 M Semrush visits lastest month: 1.87 K
- Host name: 101.0.153.160.host.secureserver.net
- IP address: 160.153.0.101
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "MimiVax"
MimiVax, Inc. - LinkedIn
BTIF portfolio company MimiVax, Inc. is developing SurVaxM, an investigational peptide vaccine that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other...See details»
FDA Expands Orphan Drug Designation for SurVaxM, …
The supplemental designation awarded to MimiVax Inc. now applies to SurVaxM as treatment for not just adult glioblastoma but a broader category of cancerous brain tumors: any malignant glioma in children or adults.See details»
MimiVax - Crunchbase Company Profile & Funding
MimiVax is a developer of immunotherapeutic vaccines and targeted therapies used to control tumor growth and recurrence. MimiVax raised $5.8 million for a cancer drug trial. View contacts for MimiVax to access new leads and connect …See details»
Roswell Park Cancer Innovation SurVaxM Granted FDA …
Oct 17, 2023 · The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company’s development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials …See details»
Roswell Park Spinoff Company Advances Toward New …
Nov 20, 2019 · MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM …See details»
MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b …
Nov 15, 2021 · MimiVax is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize SurVaxM and pipeline immunotherapeutics. For more …See details»
MimiVax Granted Fast Track Designation from FDA for …
BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and...See details»
Developing a new cancer immunotherapy, SurVaxM …
MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival...See details»
FDA Expands Orphan Drug Designation for SurVaxM, …
Aug 13, 2024 · SurVaxM is a synthetic cancer vaccine that stimulates the immune system to attack tumor cells that carry a protein called survivin. MimiVax first received orphan drug …See details»
Roswell Park Cancer Innovation SurVaxM Granted FDA …
Oct 13, 2023 · The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company’s development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials …See details»
FDA Grants Fast Track Designation to SurVaxM in …
Oct 12, 2023 · SurVaxM is a first-of-its-kind immunotherapy that stimulates the immune system to attack survivin, which is present in 95% of glioblastomas. Immune assays have shown that SurVaxM generates...See details»
US FDA awards Supplemental Orphan Drug Designation to …
May 30, 2024 · MimiVax, Inc. is a Delaware -incorporated, clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment.See details»
Roswell Park-Developed Immunotherapy Now Part of Nationwide …
Jun 7, 2022 · The vaccine, currently being developed by MimiVax LLC, is a unique immunotherapy that stimulates a patient’s immune system to target the molecule survivin, …See details»
MimiVax Announces New Investments to Support Clinical …
BUFFALO, N.Y., Jan. 9, 2024 /PRNewswire/ -- MimiVax, Inc., a biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and …See details»
FDA Grants Fast Track Designation for MimiVax’s SurVaxM
Oct 17, 2023 · MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced in a company press release that the FDA has …See details»
MimiVax Raises Funding - finsmes.com
Jan 12, 2024 · MimiVax, a NYC-based biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, raised an …See details»
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for …
Dec 15, 2022 · SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma …See details»
Roswell Park Opens Phase 2B Randomized Clinical Trial of …
Feb 4, 2022 · The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012. Currently recruiting, the phase 2B randomized SURVIVE …See details»
MimiVax Phase 2 study of SurVaxM in combination with …
May 30, 2020 · MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline …See details»
MimiVax Announces Positive Final Data from the Phase IIa Study …
Dec 15, 2022 · SurVaxM is a first-in-class, patented peptide mimic immunogen that targets survivin, a cell-survival protein present in 95% of glioblastomas and in many other cancers. …See details»